earnings
confidence high
sentiment negative
materiality 0.60
Outlook Therapeutics Q2 FY2025 net loss $46.4M; cash $7.6M; PDUFA Aug 27
Outlook Therapeutics, Inc.
2025-Q2 EPS
reported -$1.05
vs consensus -$0.40
▼ miss
(-161.7%)
- Net loss $46.4M ($1.50/share) vs $114.3M ($8.01) YoY; adjusted net loss $12.5M ($0.40) vs $22.1M ($1.55).
- Cash and equivalents $7.6M as of March 31, 2025; no revenue (pre-commercial stage).
- LYTENAVA commercial launch in Germany and UK planned for Q2 CY2025.
- FDA PDUFA goal date August 27, 2025 for ONS-5010 (bevacizumab-vikg) BLA resubmission.
- Warrant inducement expenses $33.9M and other non-cash items drove adjusted loss items.